Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ana.410400228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the Therapeutic Potential of Small Molecule of SVAK-12: A Comprehensive In Silico, In Vitro, and In Vivo Studies on its Neuroprotective Effects and Molecular Interactions in Parkinson's Disease.
Curr Med Chem
October 2024
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopamine-producing cells, and current treatments are not definitive.
- The study explored the potential of SVAK-12, a small molecule capable of crossing the blood-brain barrier, to improve cell viability and reduce neurotoxicity in various experimental settings, including in vitro, in vivo, and through molecular simulations.
- Results showed that SVAK-12 increased levels of key neurotrophic factors and boosted dopamine expression, making it a promising candidate for treating neurological disorders despite limited impact on motor symptoms in live models.
Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST.
PLoS One
October 2024
Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Background: Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice.
Methods: We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and ≥1 NMS.
Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study.
CNS Neurosci Ther
April 2024
Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Aims: This study aimed to systematically compare the effectiveness, safety, and costs of different anti-Parkinson drugs (APDs).
Methods: This is a multi-center study that retrospectively analyzed the data of 8420 outpatients with PD from 2014 to 2019 across 30 tertiary hospitals in China. The effectiveness was evaluated by changes in total dosages of APDs, normalized by levodopa equivalent dose (LED) and presented as ΔLEDs; levodopa equivalent dose cost (LEDc) represented the daily cost of APDs; and newly added diagnostics were represented as APDs-related adverse events.
[Pharmacological treatment in early rehabilitation after ischemic stroke].
Medicina (B Aires)
August 2023
Centro de Educación Médica e Investigación Clínica Norberto Quirno (CEMIC), Buenos Aires, Argentina.
There is a wealth of information on early pharmacological supportive treatment for early rehabilitation following acute ischemic stroke. This review aims to provide healthcare professionals involved in rehabilitating patients with a summary of the available evidence to assist with decision-making in their daily clinical practice. A search for randomized clinical trials and observational studies published between 1/1/2000 and 28/8/2022 was performed using PubMed, Cochrane and Epistemonikos as search engines with language restriction to english and spanish.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!